tiprankstipranks
Trending News
More News >

Neurotech International Announces Executive Director Resignation

Story Highlights
Neurotech International Announces Executive Director Resignation

Don’t Miss TipRanks’ Half-Year Sale

Neurotech International Ltd. ( (AU:NTI) ) has provided an update.

Neurotech International Limited announced the resignation of Dr. Thomas Duthy as an Executive Director, effective immediately, as he pursues other business interests. Dr. Duthy played a crucial role in the company’s clinical and corporate development, including raising $19 million in capital. His departure marks a significant transition for Neurotech as it continues to advance its drug development efforts in pediatric neurological disorders.

More about Neurotech International Ltd.

Neurotech International Limited is a clinical-stage biopharmaceutical development company focusing predominantly on pediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164, and it has completed several significant clinical trials, including Phase II/III trials in Autism Spectrum Disorder (ASD) and Phase I/II trials in PANDAS/PANS and Rett Syndrome. Neurotech is also preparing for a Phase I/II clinical trial in spastic cerebral palsy.

YTD Price Performance: -48.33%

Average Trading Volume: 706,513

Technical Sentiment Signal: Buy

Current Market Cap: A$32.31M

See more data about NTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1